Tauklarify is a newly approved PET imaging drug that lets doctors see tau tangles, a hallmark of Alzheimer's disease, inside a living brain. The FDA approved it on August 14, 2026, giving adults undergoing an Alzheimer's workup a second tau-imaging option alongside an older agent called Tauvid, according to SNMMI's approval announcement. For someone newly noticing memory changes, that approval does not instantly translate into an appointment at a local imaging center. What follows separates what the FDA has actually established about Tauklarify from what is still being worked out — accuracy, access, and where it fits alongside other tests.
Medical information disclaimer: This article is for general educational purposes only and does not provide medical advice, diagnosis, or treatment. Always consult a physician or other qualified health professional about symptoms, medications, tests, or treatment decisions.
Table of Contents
- What Tauklarify Is and What It Is Approved to Do
- How Accurate Is a Tauklarify Scan?
- Does a Tau Scan Replace Other Alzheimer's Tests?
- Why a New Approval Doesn't Mean Easy Access Yet
- Frequently Asked Questions
What Tauklarify Is and What It Is Approved to Do
Tauklarify is the brand name for florquinitau F 18 injection, a radioactive tracer developed under the research name MK-6240 and sponsored by Lantheus. A technician injects it, and a PET scanner then images where it binds in the brain, showing the pattern and density of tau neurofibrillary tangles — twisted protein fibers that build up inside neurons as Alzheimer's progresses. The FDA's approved indication covers adults with cognitive impairment who are being evaluated for Alzheimer's disease, specifically to identify whether tau tangle pathology is present, according to NeurologyLive's coverage of the approval.
That narrow wording matters: it is a diagnostic workup tool for a specific disease process, not a general memory or dementia screen. Lantheus has explicitly stated that Tauklarify's safety and effectiveness have not been established for evaluating other tauopathies, such as progressive supranuclear palsy or corticobasal degeneration, according to NeurologyLive. A person being worked up for one of those conditions rather than Alzheimer's is outside what this scan has been validated to do.
How Accurate Is a Tauklarify Scan?
The approval rested on two blinded-read studies drawing on PET images from more than 500 subjects, spanning people with mild cognitive impairment, mild Alzheimer's dementia, and cognitively unimpaired individuals. Five independent readers, each blinded to clinical information, scored the scans against a reference standard and reached positive percent agreement of roughly 68 to 88 percent and negative percent agreement of 93 to 99 percent, according to trade press coverage of the FDA review data. In practical terms, that means a negative scan was highly reliable at ruling out tau pathology across readers, while a positive reading varied more depending on who was reading it. That spread is worth knowing before treating any single scan result as the final word.
A separate head-to-head trial, the HEAD study, enrolled 775 participants across eight North American sites and compared Tauklarify directly against Tauvid (flortaucipir). Published in The Lancet in May 2026, it reported that Tauklarify had greater discriminative accuracy for Alzheimer's-related cognitive impairment than the older tracer, according to NeurologyLive's summary. Independent, non-company-linked commentary on these numbers was still sparse at the time of approval, and published accounts do not fully agree on the exact reader-agreement figures — one cites 86 to 92 percent agreement, another cites a Fleiss' kappa of 0.86 to 0.92, according to Pharmashots. Treat precise accuracy figures as provisional until independent reviews catch up.
Does a Tau Scan Replace Other Alzheimer's Tests?
No. Lantheus and trade coverage describe tau PET as complementary to amyloid PET imaging, not a replacement for it. A positive tau scan documents that tangle pathology is present, but it is not by itself a standalone diagnostic test for Alzheimer's disease, according to Diagnostic Imaging's coverage of the SNMMI announcement.
Alzheimer's disease is defined by two overlapping protein problems: amyloid plaques outside neurons and tau tangles inside them. A full workup typically still draws on clinical evaluation, cognitive testing, and often amyloid imaging or other biomarkers, with tau PET adding one more piece of biological evidence rather than standing in for the rest. For a patient and family, this means a referral for a Tauklarify scan is more likely to come after other evaluation has already started, as an additional data point for a neurologist building a fuller picture — not as the first or only test ordered.
Why a New Approval Doesn't Mean Easy Access Yet
Tauklarify is only the second FDA-approved tau-targeted PET agent; Tauvid was the first, approved back in 2020. That gives the field two tracers now, but Tauklarify carries far less real-world use history than amyloid PET agents, which have been in routine clinical use for longer, according to company coverage of the approval.
At the time of approval, Lantheus had not finalized a commercial launch plan or price for Tauklarify and said it was still assessing the path to broader availability, according to Pharmaceutical Technology. That means practical patient access — which imaging centers will offer it, what it will cost, and whether insurers will cover it for a given workup — was not yet settled when the approval was announced. For a reader with new memory symptoms, the realistic near-term step is a conversation with a neurologist or memory-disorder specialist about whether a tau PET scan is appropriate, and whether it is actually offered nearby, rather than requesting Tauklarify by name at a general imaging center.
Frequently Asked Questions
Is Tauklarify the same as Tauvid?
No. Both are FDA-approved PET tracers for tau tangles, but Tauklarify (florquinitau F 18, approved August 2026) is newer than Tauvid (flortaucipir, approved 2020), and a head-to-head trial reported Tauklarify had greater discriminative accuracy for Alzheimer's-related impairment, according to NeurologyLive.
Can Tauklarify diagnose Alzheimer's disease by itself?
No. It documents tau tangle pathology but is described as complementary to amyloid PET, not a standalone diagnostic test, according to Diagnostic Imaging.
Can Tauklarify be used to evaluate conditions other than Alzheimer's disease?
Lantheus states its safety and effectiveness have not been established for other tauopathies, such as progressive supranuclear palsy or corticobasal degeneration, according to NeurologyLive.
You Might Also Like
- Tauklarify Imaging for Alzheimer’s Tau Tangles in 2026: How Adults With New Memory Symptoms Can Compare Testing Options
- PrecivityAD2 and Younger-Onset Alzheimer’s Diagnosis in 2026: What Is Established and What Remains Uncertain for Adults With New Memory Symptoms
- PrecivityAD2 as an Adjunct to a 2026 Alzheimer’s Assessment: What Is Established and What Remains Uncertain for Adults With New Memory Symptoms
